Clinical and molecular correlates of virulence in Escherichia coli causing bloodstream infection following transrectal ultrasound-guided (TRUS) prostate biopsy

Journal of Antimicrobial Chemotherapy

Volumn 68, Issue 12, 2013, Pages 2898-2906

  Williamson, Deborah A ^a,b,c   Freeman, Joshua T ^b   Porter, Stephen ^d   Roberts, Sally ^b   Wiles, Siouxsie ^a   Paterson, David L ^e   Johnson, James R ^d  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b AUCKLAND DISTRICT HEALTH BOARD   (New Zealand)

^c INSTITUTE OF ENVIRONMENTAL SCIENCE AND RESEARCH   (New Zealand)

^d UNIVERSITY OF MINNESOTA   (United States)

^e UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Antimicrobial resistance; Fluoroquinolones; Sequence type 131

Indexed keywords

ADHESIN; ANTIINFECTIVE AGENT; CD59 ANTIGEN; INVASIN; SIDEROPHORE; TOXIN;

ADULT; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL VIRULENCE; BACTERIUM ISOLATE; BLOODSTREAM INFECTION; CLINICAL ARTICLE; ESCHERICHIA COLI; HUMAN; MALE; MULTIPLEX POLYMERASE CHAIN REACTION; PROSTATE BIOPSY; TRANSRECTAL ULTRASONOGRAPHY; UROSEPSIS;

ANTIMICROBIAL RESISTANCE; FLUOROQUINOLONES; SEQUENCE TYPE 131;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BACTEREMIA; BIOPSY; DNA, BACTERIAL; DRUG RESISTANCE, BACTERIAL; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; GENOTYPE; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; MOLECULAR EPIDEMIOLOGY; MULTIPLEX POLYMERASE CHAIN REACTION; PHYLOGENY; PROSTATE; TREATMENT OUTCOME; VIRULENCE; VIRULENCE FACTORS; YOUNG ADULT;

EID: 84887561099     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkt276     Document Type: Article

References (44)

1. Heidenreich A, Aus G, BollaMet al. EAU guidelines on prostate cancer. Eur Urol 2008; 53: 68-80.
2. Loeb S, Carter HB, Berndt SI et al. Complications after prostate biopsy: data from SEER-Medicare. J Urol 2011; 186: 1830-1834.
3. Aron M, Rajeev TP, Gupta NP. Antibiotic prophylaxis for transrectal needle biopsy of the prostate: a randomized controlled study. BJU Int 2000; 85: 682-685.
4. Crawford ED, Haynes AL Jr, Story MW et al. Prevention of urinary tract infection and sepsis following transrectal prostatic biopsy. J Urol 1982; 127: 449-451.
5. Otrock ZK, Oghlakian GO, Salamoun MM et al. Incidence of urinary tract infection following transrectal ultrasound guided prostate biopsy at a tertiary-care medical center in Lebanon. Infect Control Hosp Epidemiol 2004; 25: 873-877.
6. Nam RK, Saskin R, Lee Y et al. Increasing hospital admission rates for urological complications after transrectal ultrasound guided prostate biopsy. J Urol 2010; 183: 963-8.
7. Simsir A, Kismali E, Mammadov R et al. Is it possible to predict sepsis, the most serious complication in prostate biopsy? Urol Int 2010; 84: 395-399.
8. Horcajada JP, Busto M, Grau S et al. High prevalence of extendedspectrum b-lactamase-producing Enterobacteriaceae in bacteremia after transrectal ultrasound-guided prostate biopsy: a need for changing preventive protocol. Urology 2009; 74: 1195-1199.
9. Loeb S, Den Heuvel S.V., Zhu X et al. Infectious complications and hospital admissions after prostate biopsy in a European randomized trial. Eur Urol 2012; 61: 1110-1114.
10. Williamson DA, Barrett LK, Rogers BA et al. Infectious complications following transrectal ultrasound-guided prostate biopsy: new challenges in the era of multidrug-resistant Escherichia coli. Clin Infect Dis 2013; 57: 267-274.
11. Williamson DA, Roberts SA, Paterson DL et al. Escherichia coli bloodstream infection after transrectal ultrasound-guided prostate biopsy: implications of fluoroquinolone-resistant sequence type 131 as a major causative pathogen. Clin Infect Dis 2012; 54: 1406-1412.
12. Assimacopoulos A, Johnston B, Clabots C et al. Post-prostate biopsy infection with Escherichia coli ST131 leading to epididymo-orchitis and meningitis caused by Gram-negative bacilli. J Clin Microbiol 2012; 50: 4157-4159.
13. Rogers BR, BaturaD, Gopal Rao G. Escherichia coli bloodstreaminfection after transrectal ultrasound-guided prostate biopsy: our experience in North-West London. Clin Infect Dis 2013; 56: 465-466.
14. Johnson JR, Tchesnokova V, Johnston B et al. Abrupt emergence of a single dominant multidrug-resistant strain of Escherichia coli. J Infect Dis 2013; 207: 919-928.
15. Rogers BA, Sidjabat HE, Paterson DL. Escherichia coli O25b-ST131: a pandemic, multiresistant, community-associated strain. J Antimicrob Chemother 2011; 66: 1-14.
16. Sannes MR, Kuskowski MA, Owens K et al. Virulence factor profiles and phylogenetic background of Escherichia coli isolates from veterans with bacteremia and uninfected control subjects. J Infect Dis 2004; 190: 2121-2128.
17. Bukh AS, Schonheyder HC, Emmersen JM et al. Escherichia coli phylogenetic groups are associated with site of infection and level of antibiotic resistance in community-acquired bacteraemia: a 10 year population-based study in Denmark. J Antimicrob Chemother 2009; 64: 163-168.
18. Johnson JR, Johnston B, Clabots C et al. Escherichia coli sequence type ST131 as the major cause of serious multidrug-resistant E. coli infections in the United States. Clin Infect Dis 2010; 51: 286-294.
19. Clermont O, Lavollay M, Vimont S et al. The CTX-M-15-producing Escherichia coli diffusing clone belongs to a highly virulent B2 phylogenetic subgroup. J Antimicrob Chemother 2008; 61: 1024-1028.
20. Le Gall T, Clermont O, Gouriou S et al. Extraintestinal virulence is a coincidental by-product of commensalism in B2 phylogenetic group Escherichia coli strains. Mol Biol Evol 2007; 24: 2373-2384.
21. Nowrouzian FL, Adlerberth I, Wold AE. Enhanced persistence in the colonic microbiota of Escherichia coli strains belonging to phylogenetic group B2: role of virulence factors and adherence to colonic cells. Microbes Infect 2006; 8: 834-840.
22. Chung HC, Lai CH, Lin JN et al. Bacteremia caused by extendedspectrum- b-lactamase-producing Escherichia coli sequence type ST131 and non-ST131 clones: comparison of demographic data, clinical features, and mortality. Antimicrob Agents Chemother 2012; 56: 618-622.
23. Charlson ME, Pompei P, Ales KL et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987; 40: 373-383.
24. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing: Twenty-second Informational Supplement M100-S22. CLSI,Wayne, PA, USA, 2012.
25. Magiorakos AP, Srinivasan A, Carey RB et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect 2012; 18: 268-281.
26. Johnson JR, Menard M, Johnston B et al. Epidemic clonal groups of Escherichia coli as a cause of antimicrobial-resistant urinary tract infections in Canada, 2002 to 2004. Antimicrob Agents Chemother 2009; 53: 2733-2739.
27. Johnson JR, Johnston B, Clabots C et al. Escherichia coli sequence type ST131 as an emerging fluoroquinolone-resistant uropathogen among renal transplant recipients. Antimicrob Agents Chemother 2010; 54: 546-550.
28. Clermont O, Bonacorsi S, Bingen E. Rapid and simple determination of the Escherichia coli phylogenetic group. Appl Environ Microbiol 2000; 66: 4555-4558.
29. Johnson JR, Urban C, Weissman SJ et al. Molecular epidemiological analysis of Escherichia coli sequence type ST131 (O25:H4) and blaCTX-M-15 among extended-spectrum-b-lactamase-producing E. coli from the United States, 2000 to 2009. Antimicrob Agents Chemother 2012; 56: 2364-70.
30. Johnson JR, Murray AC, Gajewski A et al. Isolation and molecular characterization of nalidixic acid-resistant extraintestinal pathogenic Escherichia coli from retail chicken products. Antimicrob Agents Chemother 2003; 47: 2161-2168.
31. Duplessis CA, Bavaro M, Simons MP et al. Rectal cultures before transrectal ultrasound-guided prostate biopsy reduce post-prostatic biopsy infection rates. Urology 2012; 79: 556-561.
32. Lipsky BA. Urinary tract infections in men. Epidemiology, pathophysiology, diagnosis, and treatment. Ann Intern Med 1989; 110: 138-150.
33. Johnson JR, Scheutz F, Ulleryd P et al. Phylogenetic and pathotypic comparison of concurrent urine and rectal Escherichia coli isolates from menwith febrile urinary tract infection. J Clin Microbiol 2005;43: 3895-3900.
34. Zhang L, Foxman B, Marrs C. Both urinary and rectal Escherichia coli isolates are dominated by strains of phylogenetic group B2. J Clin Microbiol 2002; 40: 3951-3955.
35. Jadhav S, Hussain A, Devi S et al. Virulence characteristics and genetic affinities of multiple drug resistant uropathogenic Escherichia coli from a semi urban locality in India. PLoS One 2011; 6: e18063.
36. Steensels D, Slabbaert K, De Wever L et al. Fluoroquinolone-resistant E. coli in intestinal flora of patients undergoing transrectal ultrasoundguided prostate biopsy-should we reassess our practices for antibiotic prophylaxis? Clin Microbiol Infect 2012; 18: 575-581.
37. Liss MA, Nakamura KK, Peterson EM.Comparison of broth enhancement to direct plating for screening of rectal cultures for ciprofloxacin-resistant Escherichia coli. J Clin Microbiol 2013; 51: 249-252.
38. Ender PT, Gajanana D, Johnston B et al. Transmission of an extended-spectrum-b-lactamase-producing Escherichia coli (sequence type ST131) strain between a father and daughter resulting in septic shock and emphysematous pyelonephritis. J Clin Microbiol 2009; 47: 3780-2.
39. Vigil KJ, Johnson JR, Johnston BD et al. Escherichia coli pyomyositis: an emerging infectious disease among patients with hematologic malignancies. Clin Infect Dis 2010; 50: 374-380.
40. Johnson JR, Anderson JT, Clabots C et al.Within-household sharing of a fluoroquinolone-resistant Escherichia coli sequence type ST131 strain causing pediatric osteoarticular infection. Pediatr Infect Dis J 2010; 29: 473-475.
41. Johnson JR, Porter SB, ZhanelG et al. Virulence of Escherichia coli clinical isolates in a murine sepsis model in relation to sequence type ST131 status, fluoroquinolone resistance, and virulence genotype. Infect Immun 2012; 80: 1554-1562.
42. Lavigne JP, Vergunst AC, Goret L et al. Virulence potential and genomic mapping of the worldwide clone Escherichia coli ST131. PLoS One 2012; 7: e34294.
43. Gibreel TM, Dodgson AR, Cheesbrough J et al. High metabolic potential maycontribute to the successofST131uropathogenicEscherichia coli. J Clin Microbiol 2012; 50: 3202-3207.
44. Vimont S, Boyd A, Bleibtreu A et al. The CTX-M-15-producing Escherichia coli clone O25b: H4-ST131 has high intestine colonization and urinary tract infection abilities. PLoS One 2012; 7: e46547.